Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.
Andrew T. Kuykendall, MD
Advertisement
Articles by Andrew T. Kuykendall, MD
Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.
Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.
Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).
Advertisement
Latest Updated Articles
Dr. Kuykendall on the Potential for Momelotinib in MyelofibrosisPublished: November 2nd 2021 | Updated:
Dr. Kuykendall on the Impact of Ruxolitinib in Myeloproliferative NeoplasmsPublished: August 31st 2018 | Updated:
Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in MyelofibrosisPublished: October 17th 2019 | Updated:
Dr. Kuykendall on the Approval of Fedratinib in MyelofibrosisPublished: February 26th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5